ATTAIN-1

Phase 3 clinical trial of orforglipron in obesity, involving 3,127 participants over 72 weeks, comparing doses of 6, 12 and 36 mg against placebo. Published in NEJM in September 2025, it showed weight losses of -7.8%, -9.3% and -12.4% respectively.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.